Tuesday, November 17, 2026

LUNG CANCER - EU GREEN FOR TWO NEW TREATMENTS - WHY A THIRD DRUG WAS REJECTED IN AMERICA





LUNG CANCER - EU GREEN FOR TWO NEW TREATMENTS - WHY A THIRD DRUG WAS REJECTED IN AMERICA - Filenews 17/11 by Marilena Panayi


Two new lung cancer drugs are one step away from European approval, while in the US a third treatment failed to secure the green light from the relevant authorities.

The decisions of the European Medicines Agency (EMA) and the American FDA, announced just two days apart, highlight the speed at which pharmaceutical companies are now developing new cancer drugs, while also highlighting the strict requirements that must be met for their approval.

In detail: On November 13, the EMA announced positive recommendations for the drugs Aumseqa and Zybrivo, which are intended for different groups of patients with non-small cell lung cancer.
Two days later, on November 15, it became known that the FDA had denied approval of ivonescimab because the clinical trial supporting the application did not demonstrate statistically significant improvement in overall patient survival.

It should be emphasized that these are three different treatments and not conflicting decisions by the two organizations regarding the same drug.

Regarding Europe, the first drug to receive a positive opinion from the EMA's Committee for Medicinal Products for Human Use is Aumseqa (aumolertinib).

This is a targeted therapy that works by inhibiting the activity of the EGFR protein when it exhibits specific mutations that promote the growth of cancer cells.

The treatment targets specific adult patients with non-small cell lung cancer and EGFR mutations.

The second drug is Zybrivo (sintilimab), an immunotherapy for adults with non-squamous non-small cell lung cancer.

Its proposed use concerns specific patients, combined with chemotherapy.

Positive opinions do not yet constitute final approvals. The marketing of the two drugs in the European Union requires the relevant decision of the European Commission.

Why the FDA said "no"

The data for ivonescimab, from the pharmaceutical company Summit Therapeutics, are different.

The application concerned administering it along with chemotherapy to patients with advanced non-small cell lung cancer and specific mutations whose disease had progressed after previous targeted therapy.

In the clinical trial, the combination reduced the relative risk of disease worsening or death by 48% compared to chemotherapy without ivonescimab.

However, the difference in overall survival did not reach the required level of statistical significance.

According to the Summit briefing, the FDA ruled that the benefit in delaying disease progression, without sufficiently documented benefit in overall survival, did not support a positive benefit-risk relationship for this particular approval.

The company claims that later analyses, with longer follow-up times, show additional encouraging results.

The American decision does not mean that the drug proved ineffective or that its development stops, but rather that the data submitted were deemed insufficient to approve this particular use.